[Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis]
- PMID: 18853022
- DOI: 10.1590/s0037-86822008000400022
[Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis]
Abstract
Twenty-five mice were infected with Leishmania amazonensis and treated with glucamine and oral miltefosine. The criteria used were pad measurements and investigations of amastigotes and cultures after treatment.
Measurements: miltefosine 2.43 mm and glucamine 3.46 mm (p: 0.05). Miltefosine smears and cultures were negative. Glucamine produced two positive smears and the cultures were positive (p < 0.05). Miltefosine was similar to or better than glucamine.
Similar articles
-
Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.J Infect Dis. 2012 Feb 15;205(4):684-92. doi: 10.1093/infdis/jir816. Epub 2012 Jan 11. J Infect Dis. 2012. PMID: 22238470 Free PMC article. Clinical Trial.
-
Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.Am J Trop Med Hyg. 2010 Aug;83(2):351-6. doi: 10.4269/ajtmh.2010.10-0060. Am J Trop Med Hyg. 2010. PMID: 20682881 Free PMC article. Clinical Trial.
-
Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.J Antimicrob Chemother. 2015 Dec;70(12):3283-90. doi: 10.1093/jac/dkv254. Epub 2015 Sep 7. J Antimicrob Chemother. 2015. PMID: 26346991
-
American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.Trop Med Int Health. 2019 Apr;24(4):380-391. doi: 10.1111/tmi.13210. Epub 2019 Feb 19. Trop Med Int Health. 2019. PMID: 30681239 Review.
-
Treatment of New World cutaneous leishmaniasis with miltefosine.Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S34-40. doi: 10.1016/j.trstmh.2006.02.022. Epub 2006 Aug 22. Trans R Soc Trop Med Hyg. 2006. PMID: 16930649 Review.
Cited by
-
Repositioning of Tamoxifen in Surface-Modified Nanocapsules as a Promising Oral Treatment for Visceral Leishmaniasis.Pharmaceutics. 2021 Jul 10;13(7):1061. doi: 10.3390/pharmaceutics13071061. Pharmaceutics. 2021. PMID: 34371752 Free PMC article.
-
Compared Antileishmanial Activity of Clomiphene and Tamoxifen.Biomedicines. 2024 Oct 9;12(10):2290. doi: 10.3390/biomedicines12102290. Biomedicines. 2024. PMID: 39457604 Free PMC article.
-
Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study.PLoS One. 2015 Nov 17;10(11):e0141788. doi: 10.1371/journal.pone.0141788. eCollection 2015. PLoS One. 2015. PMID: 26574746 Free PMC article.
-
Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis.J Parasit Dis. 2016 Jun;40(2):475-84. doi: 10.1007/s12639-014-0529-0. Epub 2014 Aug 31. J Parasit Dis. 2016. PMID: 27413324 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources